Falcon Point Capital LLC raised its position in Arrowhead Research Corp. (NASDAQ:ARWR) by 12.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,147 shares of the company’s stock after buying an additional 5,458 shares during the period. Falcon Point Capital LLC’s holdings in Arrowhead Research Corp. were worth $261,000 as of its most recent filing with the SEC.
Separately, Geode Capital Management LLC raised its stake in Arrowhead Research Corp. by 8.3% in the first quarter. Geode Capital Management LLC now owns 408,065 shares of the company’s stock worth $1,966,000 after buying an additional 31,293 shares in the last quarter. Institutional investors own 33.92% of the company’s stock.
Arrowhead Research Corp. (NASDAQ:ARWR) traded down 2.49% on Monday, hitting $7.04. 432,863 shares of the stock were exchanged. Arrowhead Research Corp. has a 12 month low of $3.07 and a 12 month high of $8.22. The stock’s market cap is $427.68 million. The company has a 50-day moving average of $6.93 and a 200-day moving average of $5.90.
Arrowhead Research Corp. (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. The firm had revenue of $39.58 million for the quarter, compared to analyst estimates of $0.05 million. Arrowhead Research Corp. had a negative net margin of 48,980.81% and a negative return on equity of 100.50%. The company’s revenue for the quarter was down 68.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.27) EPS. On average, equities analysts predict that Arrowhead Research Corp. will post ($1.31) EPS for the current year.
A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Arrowhead Research Corp. in a research report on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Arrowhead Research Corp. in a research report on Wednesday, September 7th. William Blair assumed coverage on shares of Arrowhead Research Corp. in a research report on Friday, August 19th. They issued an “outperform” rating for the company. Finally, Piper Jaffray Cos. reduced their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.11.
In other news, CFO Kenneth Allen Myszkowski sold 13,100 shares of Arrowhead Research Corp. stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $8.00, for a total transaction of $104,800.00. Following the sale, the chief financial officer now owns 128,789 shares of the company’s stock, valued at approximately $1,030,312. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.90% of the company’s stock.
About Arrowhead Research Corp.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Research Corp. (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.